Skip Navigation


JAC Advance Access originally published online on November 1, 2002
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
50/6/1065    most recent
dkf252v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Krzyszton-Russjan, J.
Right arrow Articles by Hryniewicz, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krzyszton-Russjan, J.
Right arrow Articles by Hryniewicz, W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2002) 50, 1065-1069
© 2002 The British Society for Antimicrobial Chemotherapy

The first Staphylococcus aureus isolates with reduced susceptibility to vancomycin in Poland

Jolanta Krzyszton-Russjan1, Marek Gniadkowski1, Hanna Polowniak-Pracka2, Elzbieta Hagmajer2 and Waleria Hryniewicz1,*

1 Sera and Vaccines Central Research Laboratory, ul. Chelmska 30/34, 00-725 Warsaw; 2 The Maria Sklodowska-Curie Memorial Centre and Institute of Oncology, ul. Roentgena 5, 02-185 Warsaw, Poland

Received 25 March 2002; returned 8 August 2002; revised 30 August 2002; accepted 16 September 2002

The first heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) isolates to be identified in Poland were characterized. They were recovered in two Warsaw hospitals and, although in one of these the identification coincided with unsuccessful glycopeptide therapy, the selection conditions and clinical significance of the organisms remain unclear. Molecular typing revealed that the isolates were closely related and belonged to an international methicillin-resistant S. aureus (MRSA) clone known as ‘Iberian’. The analysis of epidemiologically related MRSA isolates and some archival Polish MRSA isolates of the same clone indicated that the hVISA phenotype has been present in the MRSA populations of some hospitals in Poland since at least 1998.

* Corresponding author. Tel: +48-22-841-33-67; Fax: +48-22-841-29-49; E-mail: waleria{at}urania.il.waw.pl


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Microbiol.Home page
A. Luczak-Kadlubowska, A. Sulikowska, J. Empel, A. Piasecka, M. Orczykowska, A. Kozinska, and W. Hryniewicz
Countrywide Molecular Survey of Methicillin-Resistant Staphylococcus aureus Strains in Poland
J. Clin. Microbiol., September 1, 2008; 46(9): 2930 - 2937.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
A. Luczak-Kadlubowska, J. Krzyszton-Russjan, and W. Hryniewicz
Characteristics of Staphylococcus aureus Strains Isolated in Poland in 1996 to 2004 That Were Deficient in Species-Specific Proteins
J. Clin. Microbiol., November 1, 2006; 44(11): 4018 - 4024.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
H. Wisplinghoff, B. Ewertz, S. Wisplinghoff, D. Stefanik, G. Plum, F. Perdreau-Remington, and H. Seifert
Molecular Evolution of Methicillin-Resistant Staphylococcus aureus in the Metropolitan Area of Cologne, Germany, from 1984 to 1998
J. Clin. Microbiol., November 1, 2005; 43(11): 5445 - 5451.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.